BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28036258)

  • 1. Epstein-Barr virus EBNA2 directs doxorubicin resistance of B cell lymphoma through CCL3 and CCL4-mediated activation of NF-κB and Btk.
    Kim JH; Kim WS; Hong JY; Ryu KJ; Kim SJ; Park C
    Oncotarget; 2017 Jan; 8(3):5361-5370. PubMed ID: 28036258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.
    Li C; Romero-Masters JC; Huebner S; Ohashi M; Hayes M; Bristol JA; Nelson SE; Eichelberg MR; Van Sciver N; Ranheim EA; Scott RS; Johannsen EC; Kenney SC
    PLoS Pathog; 2020 Jun; 16(6):e1008590. PubMed ID: 32542010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus-encoded EBNA2 downregulates ICOSL by inducing miR-24 in B-cell lymphoma.
    Leopizzi M; Mundo L; Messina E; Campolo F; Lazzi S; Angeloni A; Marchese C; Leoncini L; Giordano C; Slack F; Trivedi P; Anastasiadou E
    Blood; 2024 Feb; 143(5):429-443. PubMed ID: 37847858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
    Anastasiadou E; Stroopinsky D; Alimperti S; Jiao AL; Pyzer AR; Cippitelli C; Pepe G; Severa M; Rosenblatt J; Etna MP; Rieger S; Kempkes B; Coccia EM; Sui SJH; Chen CS; Uccini S; Avigan D; Faggioni A; Trivedi P; Slack FJ
    Leukemia; 2019 Jan; 33(1):132-147. PubMed ID: 29946193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancer Control of MicroRNA miR-155 Expression in Epstein-Barr Virus-Infected B Cells.
    Wood CD; Carvell T; Gunnell A; Ojeniyi OO; Osborne C; West MJ
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30021904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders/lymphomas.
    Ando M; Sato Y; Takata K; Nomoto J; Nakamura S; Ohshima K; Takeuchi T; Orita Y; Kobayashi Y; Yoshino T
    PLoS One; 2013; 8(2):e56741. PubMed ID: 23418597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma.
    Takahashi K; Sivina M; Hoellenriegel J; Oki Y; Hagemeister FB; Fayad L; Romaguera JE; Fowler N; Fanale MA; Kwak LW; Samaniego F; Neelapu S; Xiao L; Huang X; Kantarjian H; Keating MJ; Wierda W; Fu K; Chan WC; Vose JM; O'Brien S; Davis RE; Burger JA
    Br J Haematol; 2015 Dec; 171(5):726-35. PubMed ID: 26358140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiling of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways.
    Kato H; Karube K; Yamamoto K; Takizawa J; Tsuzuki S; Yatabe Y; Kanda T; Katayama M; Ozawa Y; Ishitsuka K; Okamoto M; Kinoshita T; Ohshima K; Nakamura S; Morishima Y; Seto M
    Cancer Sci; 2014 May; 105(5):537-44. PubMed ID: 24581222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Notch1, Notch2, and Epstein-Barr virus-encoded nuclear antigen 2 signaling differentially affects proliferation and survival of Epstein-Barr virus-infected B cells.
    Kohlhof H; Hampel F; Hoffmann R; Burtscher H; Weidle UH; Hölzel M; Eick D; Zimber-Strobl U; Strobl LJ
    Blood; 2009 May; 113(22):5506-15. PubMed ID: 19339697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodgkin's lymphoma cells.
    Boccellato F; Anastasiadou E; Rosato P; Kempkes B; Frati L; Faggioni A; Trivedi P
    J Virol; 2007 Mar; 81(5):2274-82. PubMed ID: 17151114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The NP9 protein encoded by the human endogenous retrovirus HERV-K(HML-2) negatively regulates gene activation of the Epstein-Barr virus nuclear antigen 2 (EBNA2).
    Gross H; Barth S; Pfuhl T; Willnecker V; Spurk A; Gurtsevitch V; Sauter M; Hu B; Noessner E; Mueller-Lantzsch N; Kremmer E; Grässer FA
    Int J Cancer; 2011 Sep; 129(5):1105-15. PubMed ID: 21710493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autocrine CCL3 and CCL4 induced by the oncoprotein LMP1 promote Epstein-Barr virus-triggered B cell proliferation.
    Tsai SC; Lin SJ; Lin CJ; Chou YC; Lin JH; Yeh TH; Chen MR; Huang LM; Lu MY; Huang YC; Chen HY; Tsai CH
    J Virol; 2013 Aug; 87(16):9041-52. PubMed ID: 23760235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent downregulation of BTB and CNC homology 2 expression in Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Noujima-Harada M; Takata K; Miyata-Takata T; Sakurai H; Igarashi K; Ito E; Nagakita K; Taniguchi K; Ohnishi N; Omote S; Tabata T; Sato Y; Yoshino T
    Cancer Sci; 2017 May; 108(5):1071-1079. PubMed ID: 28256087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr Virus Nuclear Antigen 3 (EBNA3) Proteins Regulate EBNA2 Binding to Distinct RBPJ Genomic Sites.
    Wang A; Welch R; Zhao B; Ta T; Keleş S; Johannsen E
    J Virol; 2015 Dec; 90(6):2906-19. PubMed ID: 26719268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJ kappa-dependent pathway.
    Pegman PM; Smith SM; D'Souza BN; Loughran ST; Maier S; Kempkes B; Cahill PA; Simmons MJ; Gélinas C; Walls D
    J Virol; 2006 Aug; 80(16):8133-44. PubMed ID: 16873269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
    Leong IT; Fernandes BJ; Mock D
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus (EBV) provides survival factors to EBV
    Wu L; Ehlin-Henriksson B; Zhou X; Zhu H; Ernberg I; Kis LL; Klein G
    Immunology; 2017 Dec; 152(4):562-573. PubMed ID: 28699226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein-Barr virus-associated T-cell lymphoma: nuclear factor-kappa B pathway as a potential therapeutic target.
    Chuang HC; Lay JD; Hsieh WC; Su IJ
    Cancer Sci; 2007 Sep; 98(9):1281-7. PubMed ID: 17627615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Europe expression of EBNA2 is associated with poor survival in EBV-positive diffuse large B-cell lymphoma of the elderly.
    Stuhlmann-Laeisz C; Borchert A; Quintanilla-Martinez L; Hoeller S; Tzankov A; Oschlies I; Kreuz M; Trappe R; Klapper W
    Leuk Lymphoma; 2016; 57(1):39-44. PubMed ID: 25899404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in EBNA2 and LMP-1 carboxy terminal region sequences of Epstein-Barr virus type A between the tumors in a multiple cancer patient.
    Higa M; Kinjo T; Miyagi J; Sakumoto N; Iwamasa T; Kishaba M; Sunakawa H
    Pathol Res Pract; 2001; 197(6):401-9. PubMed ID: 11432667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.